Dr. Jonathan Barrera-Calix, MD

Dr. Barrera-Calix practices at Swedish Cherry Hill Campus in Seattle, Washington, part of Providence Health & Services.

Dr. Barrera-Calix's NPI, 1356797864, was assigned on May 13, 2016. Dr. Barrera-Calix holds Washington license MD61169639.

Dr. Barrera-Calix's primary practice is Swedish Cherry Hill Campus, at 500 17th Avenue, Seattle, WA 98122 in King County. The practice phone is (206) 320-2000.

Dr. Barrera-Calix's primary practice is Swedish Cherry Hill Campus in Seattle, Washington, part of Providence Health & Services. Dr. Barrera-Calix is also affiliated with Swedish First Hill Campus. The medical group on file is Swedish Health Services. Dmand AI also links Dr. Barrera-Calix to 2 more hospitals, 3 medical groups, 1 group practice or clinic, 1 hospital outpatient department and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barrera-Calix practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Barrera-Calix's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Barrera-Calix is licensed in Washington.

CMS data shows 396 Medicare services from Dr. Barrera-Calix across 3 procedure codes in 2024, for 109 Medicare patients. Medicare paid $41,998 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 109 Medicare patients who saw Dr. Barrera-Calix in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have chronic kidney disease, and 75% have heart failure. 30% are also on Medicaid. Their average risk score is 6.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Barrera-Calix's median patient age at 70, with 39% women.

In 2024, Dr. Barrera-Calix wrote 22 Medicare Part D claims for 14 patients. 86% of them were for generic drugs. They cover 13 drugs, with $28,215 in total drug cost. In 2022, CMS named 289 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Barrera-Calix for performance year 2024, reported as part of a group. Dr. Barrera-Calix accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 5 general payments to Dr. Barrera-Calix from 5 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 76% of the total. Alexion Pharmaceuticals, Inc. paid the most, $134.